Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
View Patent ↗The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.
1. A method for generating an attenuated influenza virus comprising:
(a) introducing a recombinant DNA comprising the coding sequence of an influenza virus NS1 gene into a cell that provides the other influenza virus gene segments and viral proteins required to produce influenza virus particles, wherein the NS1 gene encodes a truncated NS1 protein composed of between 90 and 130 N-terminal amino acid residues of the NS1 protein of an influenza virus strain, so that the NS1 protein has an impaired ability to antagonize the cellular interferon response; and
(b) culturing the cell, wherein the attenuated influenza virus is produced.
2. The method of claim 1 , wherein the NS1 gene encodes a truncated NS1 protein of between 90 and 100 N-terminal amino acid residues of the NS1 protein of the influenza virus strain.
3. The method of claim 1 , wherein the NS1 gene encodes a truncated NS1 protein of between 100 and 110 N-terminal amino acid residues of the NS1 protein of the influenza virus strain.
4. The method of claim 1 , wherein the NS1 gene encodes a truncated NS1 protein of between 110 and 120 N-terminal amino acid residues of the NS1 protein of the influenza virus strain.
5. The method of claim 1 , wherein the NS1 gene encodes a truncated NS1 protein of between 120 and 130 N-terminal amino acid residues of the NS1 protein of the influenza virus strain.
6. The method of claim 1 , wherein one of the other influenza virus gene segments encodes a heterologous sequence.
7. The method of claim 6 , wherein the heterologous sequence is an antigen of an influenza virus strain variant.
8. The method of claim 6 , wherein the influenza virus gene segment encoding the heterologous sequence is the hemagglutinin or neuraminidase gene segment.
9. The method of claim 1 , wherein the attenuated influenza virus is an influenza A virus.
10. The method of claim 1 , wherein the attenuated influenza virus is an influenza B virus.
11. A method for generating an attenuated influenza virus comprising:
(a) introducing a recombinant DNA comprising the coding sequence of an influenza virus NS1 gene into a cell that provides the other influenza virus gene segments and viral proteins required to produce influenza virus particles, wherein the NS1 gene encodes a truncated NS1 protein composed of between 60 and 70 N-terminal amino acid residues of the NS1 protein of an influenza virus strain, so that the NS1 protein has an impaired ability to antagonize the cellular interferon response; and
(b) culturing the cell, wherein the attenuated influenza virus is produced.
12. The method of claim 11 , wherein one of the other influenza virus gene segments encodes a heterologous sequence.
13. The method of claim 12 , wherein the heterologous sequence is an antigen of an influenza virus strain variant.
14. The method of claim 12 , wherein the influenza virus gene segment encoding the heterologous sequence is the hemagglutinin or neuraminidase gene segment.
15. The method of claim 11 , wherein the attenuated influenza virus is an influenza A virus.
16. The method of claim 11 , wherein the attenuated influenza virus is an influenza B virus.
17. A method for generating an attenuated influenza virus comprising:
(a) introducing a recombinant DNA comprising the coding sequence of an influenza virus NS1 gene into a cell that provides the other viral segments and viral proteins required to produce influenza virus particles, wherein the NS1 gene encodes a truncated NS1 protein composed of amino acid residues 1 to 130, amino acid residues 1 to 120, amino acid residues 1 to 110, amino acid residues 1 to 100, amino acid residues 1 to 99, amino acid residues 1 to 90, amino acid residues 1 to 89, amino acid residues 1 to 70, or amino acid residues 1 to 60 of the NS1 protein of an influenza virus strain, so that the NS1 protein has an impaired ability to antagonize the cellular interferon response; and
(b) culturing the cell, wherein the attenuated influenza virus is produced.
18. The method of claim 17 , wherein one of the other influenza virus gene segments encodes a heterologous sequence.
19. The method of claim 18 , wherein the heterologous sequence is an antigen of an influenza virus strain variant.
20. The method of claim 18 , wherein the influenza virus gene segment encoding the heterologous sequence is the hemagglutinin or neuraminidase gene segment.
21. The method of claim 17 , wherein the attenuated influenza virus is an influenza A virus.
22. The method of claim 17 , wherein the attenuated influenza virus is an influenza B virus.
23. A method for generating an attenuated influenza virus comprising:
(a) introducing a recombinant DNA comprising the coding sequence of an influenza virus NS1 gene into a cell that provides the other influenza virus gene segments and viral proteins required to produce influenza virus particles, wherein the NS1 gene encodes a truncated NS1 protein composed of between 90 and 100, 100 and 110, or 70 and 80 N-terminal amino acid residues of the NS1 protein of an influenza virus strain, so that the NS1 protein has an impaired ability to antagonize the cellular interferon response, and wherein one of the other influenza virus gene segments encodes a heterologous sequence; and
(b) culturing the cell, wherein the attenuated influenza virus is produced.
24. The method of claim 23 , wherein the influenza virus NS1 gene encodes a truncated NS1 protein composed of between 70 and 80 N-terminal amino acid residues of the NS1 protein of the influenza virus strain.
25. The method of claim 23 , wherein the heterologous sequence is an antigen of an influenza virus strain variant.
26. The method of claim 23 , wherein the influenza virus gene segment encoding the heterologous sequence is the hemagglutinin or neuraminidase gene segment.
27. The method of claim 23 , wherein the attenuated influenza virus is an influenza A virus.
28. The method of claim 23 , wherein the attenuated influenza virus is an influenza B virus.